1. Home
  2. NLOP vs SLN Comparison

NLOP vs SLN Comparison

Compare NLOP & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NLOP

Net Lease Office Properties of Beneficial Interest

HOLD

Current Price

$20.50

Market Cap

380.9M

Sector

N/A

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.98

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NLOP
SLN
Founded
N/A
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
380.9M
318.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NLOP
SLN
Price
$20.50
$5.98
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$46.00
$39.67
AVG Volume (30 Days)
207.5K
307.0K
Earning Date
02-19-2026
11-06-2025
Dividend Yield
59.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$115,901,000.00
$25,830,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.39
52 Week Low
$20.60
$1.97
52 Week High
$34.53
$8.08

Technical Indicators

Market Signals
Indicator
NLOP
SLN
Relative Strength Index (RSI) 15.99 41.89
Support Level $25.45 $5.94
Resistance Level $26.19 $6.46
Average True Range (ATR) 0.65 0.38
MACD -0.41 -0.03
Stochastic Oscillator 7.71 31.82

Price Performance

Historical Comparison
NLOP
SLN

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: